A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
NCT06362369
This study is recruiting at 4 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study near completion of the Phase 1b
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Advanced Cancer
- Advanced Solid Tumor
- Melanoma
- Metastasis
- Pleural Mesothelioma
- Renal Cell Carcinoma
- MSI-High
- Mismatch Repair Deficiency
- Colorectal Cancer
- Hepatocellular Carcinoma
- Hepatocellular Cancer
- Renal Cell Cancer
- Kidney Cancer
- Skin Cancer
- Non Small Cell Lung Cancer
- NSCLC
- Anaplastic Lymphoma Kinase Genomic Tumor Aberrations
- ALK Genomic Tumor Aberrations
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- 7 Hills Pharma, LLC
- Last updated on ClinicalTrials.gov
- April 13, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 1
- University of Colorado Cancer Center · Aurora, CO
New Hampshire · 1
- Dartmouth Hitchcock · Lebanon, NH
Rhode Island · 1
- Brown University Health Cancer Institute · Providence, RI
Texas · 1
- MD Anderson Cancer Center · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.